The board of directors of Luye Pharma Group Ltd. announced that the marketing registration of Xuezhikang Capsules has been approved in Uzbekistan for the treatment of hyperlipidemia and cardiovascular and cerebrovascular diseases caused by hyperlipidemia and atherosclerosis. Xuezhikang is a pure natural lipid-regulating drug made by fermentation of red yeast rice using modern GMP production technology, and has been on the market for over 20 years. Xuezhikang has the effect of regulating abnormal blood lipids, which can reduce total blood cholesterol, triglycerides and low density lipoprotein, increase high density lipoprotein, inhibit atherosclerotic plaque formation, protect vascular endothelial cells and inhibit lipid deposition in the liver.

It is believed that due to environmental and lifestyle factors, Uzbekistan has a high incidence of cardiovascular diseases such as ischemic heart disease, stroke, hypertension, and related cardiovascular diseases, as well as metabolic diseases such as diabetes. These constitute the main factors impacting the health and life span of residents. According to the 2019 Uzbekistan NCD Risk Factor Prevalence Survey, the incidence of hyperglycemia among a population aged 18-69, the incidence of hyperglycemia was 27.1% and the incidence of cardiovascular disease was 23.9%; amongst adults, 46.5% had high blood pressure; amongst a population aged 30-70, 53% of deaths were related to cardiovascular disease; and the incidence of cardiovascular disease has increased by 20% in the past five years and is trending younger.

The Company believes that the marketing of Xuezhikang in Uzbekistan will play a significant role in the prevention and treatment of these diseases and benefit local patients. At the same time, The Group will accelerate the promotion of Xuezhikang to more countries and regions in Central Asia and around the world. In 2019, the Group reached a strategic cooperation agreement with Astrazeneca regarding Xuezhikang products, including granting the promotional rights of Xuezhikang in Mainland China and Singapore.

The two parties signed a strategic cooperation memorandum to cooperate on the international promotion of Xuezhikang, to leverage their respective resource and product advantages in domestic and overseas markets, and to work together to accelerate the promotion of Xuezhikang to more countries and regions around the world. At present, the product is also sold in Hong Kong, China, Southeast Asia, and other markets, and the market of Xuezhikang in Latin America is also actively developing.